Showing results (111-120 of 368) with videos related to
Sort By:
Pageof 37
International Journal of Cardiology|September 18, 2012
The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetesFadi G Hage, Frans J Th Wackers, Shanti Bansal, et al.Academic Medicine : Journal of the Association of American Medical Colleges|March 28, 2006
Improving clinical productivity in the academic setting: a novel incentive plan based on utility theoryMadeline S Wilson, Keith A Joiner, Silvio E Inzucchi, et al.Diabetes Care|August 1, 2013
HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging StudyKasia J Lipska, E Margaret Warton, Elbert S Huang, et al.Diabetes Technology & Therapeutics|October 14, 2006
"Glucometrics"--assessing the quality of inpatient glucose managementPhilip A Goldberg, Janis E Bozzo, Prem G Thomas, et al.Annals of Vascular Surgery|May 20, 2026
Sodium Glucose Cotransporter-2 inhibitors are not associated with amputation after lower extremity revascularization in patients with diabetesUma D Alappan, Ashwin K Chetty, Warren Carter, et al.Diabetes Care|October 9, 2010
Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysisShanti Bansal, Frans J Th Wackers, Silvio E Inzucchi, et al.Archives of Internal Medicine|January 26, 2005
Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic strokeWalter N Kernan, Catherine M Viscoli, Silvio E Inzucchi, et al.Diabetes, Obesity & Metabolism|December 3, 2019
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, et al.Journal of Diabetes and Its Complications|May 1, 2012
Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agentsOlga V Sakharova, Ranee R Lleva, James D Dziura, et al.Diabetes, Obesity & Metabolism|August 4, 2020
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trialChristoph Wanner, Silvio E Inzucchi, Bernard Zinman, et al.Pageof 37